Inhibition of APP Secretases as a Therapy for Traumatic Brain Injury
APP secretase inhibitors, currently in AD clinical trials, may prove effective in treating TBI, as may other interventions that reduce amyloid-beta levels.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)